Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.O)

CYCC.O on Consolidated Issue listed on NASDAQ Capital Market

1.77USD
25 Jul 2017
Change (% chg)

$-0.01 (-0.56%)
Prev Close
$1.78
Open
$1.78
Day's High
$1.79
Day's Low
$1.71
Volume
616,128
Avg. Vol
727,605
52-wk High
$10.90
52-wk Low
$1.71

CYCC.O

Chart for CYCC.O

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.41
Market Cap(Mil.): $11.46
Shares Outstanding(Mil.): 6.44
Dividend: --
Yield (%): --

Financials

  CYCC.O Industry Sector
P/E (TTM): -- 214.05 15.73
EPS (TTM): -2.92 -- --
ROI: -71.04 -7.97 -8.37
ROE: -73.16 -9.29 -7.93

BRIEF-Cyclacel announces pricing of $13.2 mln underwritten public offering

* Cyclacel announces pricing of $13.2 million underwritten public offering

Jul 19 2017

BRIEF-Cyclacel Pharmaceuticals says approved extension of employment agreements with CEO and CFO

* Cyclacel pharmaceuticals - compensation and organization development committee approved extension of employment agreements with ceo spiro rombotis, cfo paul mcbarron

Jun 27 2017

BRIEF-Cyclacel Pharma files for potential offering of up to $15 mln

* Cyclacel pharmaceuticals inc- files for potential offering of up to $15 million - sec filing Source text for Eikon: Further company coverage:

May 26 2017

BRIEF-Cyclacel Pharmaceuticals Q1 loss per share $0.38

* Cyclacel pharmaceuticals reports first quarter 2017 financial results

May 11 2017

BRIEF-Intra-Cellular therapies reports Q1 loss per share $0.62

* Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update

May 10 2017

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies provides corporate update on schizophrenia program

May 01 2017

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

Apr 04 2017

BRIEF-Cyclacel Pharmaceuticals reports Q4 and full year 2016 financial results

* Cyclacel Pharmaceuticals reports fourth quarter and full year 2016 financial results

Mar 28 2017

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

UPDATE 1-Cyclacel's leukemia drug for elderly patients fails in key study

Feb 23 Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Feb 23 2017

Earnings vs. Estimates